



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/152732/2019
EMEA/V/C/004824

Chanhold (*selamectin*)

An overview of Chanhold and why it is authorised in the EU

What is Chanhold and what is it used for?

Chanhold is an antiparasitic medicine used to treat and prevent infestations with parasites that live on the skin or in the fur of cats and dogs, such as fleas and mites, as well as treating worm parasites that live inside the body. It is used in the following ways:

- to treat and prevent flea infestations in cats and dogs, by killing adult fleas, their larvae and their eggs on the animal, and in the litters of pregnant or nursing cats or dogs. It can also be used as part of a treatment for flea allergy dermatitis (skin inflammation),
- to prevent heartworm disease in cats and dogs,
- to treat ear mites in cats and dogs,
- to treat adult intestinal roundworms and intestinal hookworms in cats,
- to treat adult intestinal roundworms in dogs,
- to treat biting lice infestations in cats and dogs,
- to treat sarcoptic mange (scabies) in dogs.

Chanhold contains the active substance selamectin and is a 'generic medicine'. This means that Chanhold contains the same active substance and works in the same way as a 'reference medicine' already authorised in the European Union (EU) called Stronghold.

How is Chanhold used?

The medicine is available as a spot-on solution in 2 different concentrations (6% and 12%) and in tubes of various strengths (15, 30, 45, 60, 120, 240 and 360 mg). It can only be obtained with a prescription. The contents of the tube are squeezed onto the skin after parting the fur at the base of the neck between the shoulder blades. This small volume of liquid is absorbed through the skin and has an effect throughout the animal's body. The strength used and the number of administrations depend on the weight and species of the animal being treated, and the type of parasite. The package leaflet contains detailed information on dosage and duration of treatment.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



For more information about using Chanhold, see the package leaflet or contact your veterinarian or pharmacist.

How does Chanhold work?

Chanhold contains selamectin, which is an antiparasitic medicine that belongs to the 'ivermectin' class. Selamectin activates special proteins called 'chloride channels' on the surface of nerve and muscle cells of the parasite, allowing charged chloride particles to enter nerve cells and disrupting their normal electrical activity. This causes the paralysis or death of the parasites.

How has Chanhold been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Stronghold, and do not need to be repeated for Chanhold.

As for every medicine, the company provided studies on the quality of Chanhold. There was no need for 'bioequivalence' studies to investigate whether Chanhold is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because the composition of Chanhold is comparable to the reference medicine and when applied to the skin, the active substance in both products is expected to be absorbed in the same way.

What are the benefits and risks of Chanhold?

Because Chanhold is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

What are the precautions for the person who gives the medicine or comes into contact with the animal?

Safety information has been included in the summary of product characteristics and the package leaflet for Chanhold, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. The precautions are the same as for the reference medicine since Chanhold is a generic medicine.

Why is Chanhold authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Chanhold has been shown to be comparable to Stronghold. Therefore, the Agency's view was that, as for Stronghold, the benefit of Chanhold outweighs the identified risk and it can be authorised for use in the EU.

Other information about Chanhold

Chanhold received a marketing authorisation valid throughout the EU on 17 April 2019.

Further information on Chanhold can be found on the Agency's website: ema.europa.eu/Find/medicines/veterinary/EPAR/chanhold.

Information on the reference medicine can also be found on the Agency's website.

This overview was last updated in February 2019.